According to a new report by Polaris Market Research, the global Blood Cancer Drugs market was valued at USD 67.50 billion in 2025 and is projected to reach USD 164.04 billion by 2034, expanding at a CAGR of 10.4% over the forecast period. Growth is underpinned by the rising incidence of hematological malignancies and therapy intensification, a broad transition toward chronic,...